Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Biological Chemistry
Yet again, antibodies designed to target β-amyloid have failed. Researchers at Washington University in St. Louis tested Roche’s gantenerumab, Eli Lilly and Company’s solanezumab, or a placebo in 194 people with a genetic mutation that causes early-onset Alzheimer’s. Neither antibody slowed memory loss or cognitive decline. Both drugs have failed in Alzheimer’s trials before, but Lilly and Roche will continue to test them in people with late-onset Alzheimer’s not caused by genetic mutations.
This article has been sent to the following recipient: